Genencor, National Cancer Institute deal

GCOR licensed exclusive worldwide rights to develop and commercialize BL22 and

Read the full 110 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE